O.A. Smirnova (1), N.E. Bondarev (1), A.S. Petrova (1), K.D. Guseinov (1), N.A. Mikaya (1), A.S. Artemyeva (1), Т.V. Gorodnova (1), E.A. Nekrasova (1), O.E. Lavrynovych (1), V.O. Bashlyk (1), A.O. Nyuganen (1), A.V. Abramova (1), A.A. Sidoruk (1), E.A. Ulrikh (1, 2), T.Yu. Semiglazova (1, 2), A.F. Urmancheeva (1, 2), I.V. Berlev (1, 2)
1 N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia;
2 North-Western State Medical University n.a. I.I. Mechnikov, Saint-Petersburg, Russia
Objective: to evaluate the results of the use of dose-intensive neoadjuvant chemotherapy (NACT) with doxorubicin and cisplatin in patients with locally advanced cervical cancer stage IB2-IIB. Methods. In the patients participating in the study, the efficacy and toxi-city of 3 cycles of intravenous dose-intensive NACT according to the AP scheme (cisplatin 75 mg/m2, doxorubicin 35 mg/m2) and subsequent radical surgical intervention in 62 (89%) cases were evaluated. Results. The study involved 70 patients with locally advanced cervical cancer at the age of 27–68 years (mean age, 45 years). Against the background of the treatment, an objective response was received from 58 (83%) patients. Progression of the disease was detected in 6 (8.6%) cases; relapse of the disease was diagnosed in 2 (2.8%) patients. Neoadjuvant therapy allowed to perform radical surgical intervention in 61 (87.1%) patients. The tumor pathomorphological response of various degrees was obtained in 58 (82.8%) cases; complete clinical regression of the tumor was confirmed by a complete pathomorphological response in 5 (7.14%) of these cases. The dose-intensive regimen of chemotherapy did not lead to significant complications at the pharmacological and surgical stages of treatment. Conclusion. Analysis of the study results has showed that dose-intensive NACT is an effective method and can be considered as an alternative to standard treatment of locally advanced cervical cancer.